No. However, CCPM has begun embedding clinical decision support (CDS) into UCHealth’s EHR to notify providers if they prescribe certain medications metabolized by CYP2C19 and the patient has a known variation in the CYP2C19 gene altering his or her metabolism in a clinically-actionable way. As of August 2019, clinical decision support is available for Clopidogrel prescribed to patients with acute coronary syndromes undergoing percutaneous coronary intervention (ACS/PCI) or Voriconazole prescribed for treatment or prophylaxis of serious fungal infections.
Please note that not all medications are metabolized by CYP2C19. For medications that are metabolized by CYP2C19, CYP2C19 genotype does not impact outcomes for all medications to the same extent, or does so in an indication-specific manner.
If you are a provider and would like detailed information about clopidogrel-CYP2C19 and EHR clinical decision support, click here.
If you are a provider and would like detailed information about voriconazole-CYP2C19 and EHR clinical decision support, clear here.
For general information about CYP2C19, click here.